Speaker invited by Prof. Jakob N. Kather
Dissecting and leveraging the molecular heterogeneity of pancreatic adenocarcinoma
Rémy Nicolle is a researcher at the Centre de Recherche sur l’Inflammation in Paris, where he leads a translational research project called GeNeHetX focused on understanding the architecture and heterogeneity of pancreatic cancers.
He aims to characterize the inter- and intra-patient heterogeneity of pancreatic tumors, with the goal of aiding therapeutic innovation for this disease. Nicolle’s work involves studying the role of fatty pancreatic infiltration in pancreatic oncogenesis, as well as investigating the immunological landscape in pancreatic ductal adenocarcinoma. He utilizes computational biology approaches, such as co-regulatory network reconstruction and integrated analysis, to further his research objectives.
He also leads the INSERM group (ATIP-Avenir 2022) aiming to decipher the phenotypic heterogeneity of pancreatic diseases (focus on pancreatic adenocarcinoma), to develop clinically-applicable phenotyping tools. Using computational tools and genome-wide profiling to study the morpho-molecular heterogeneity of pancreatic tumors and for translational genomics.
Nicolle is also a co-founder of Cure51, a company likely related to his work on pancreatic cancer. Overall, his research focuses on elucidating the complex heterogeneity and architecture of pancreatic cancers, with the ultimate aim of facilitating the development of more effective therapeutic strategies.
powered by eveeno.de